Objective To investigate the efficacy of Tirofiban combined with Atorvastatin and dual antiplatelet drugs in patients with coronary atherosclerotic heart disease after percutaneous coronary intervention (PCI). Methods A total of 106 patients with coronary atherosclerotic heart disease who underwent PCI in Shenyang First People′s Hospital from March 2018 to June 2020 were selected and divided into the experimental group (53 cases) and the reference group(53 cases) by computer random number table methods according to the number of visits. The control group was treated with Clopidogrel, Aspirin and Atorvastatin after surgery, and the experimental group was treated with Tirofiban on the basis of the reference group. The cardiac function (left ventricular end-diastolic diameter [LVEDD], left ventricular end-systolic diameter [LVESD], left ventricular ejection fraction [LVEF]), platelet activating factor (PAF), growth differentiation factor 15 (GDF-15) before and after treatment and the incidence of major adverse cardiac events (MACE) at 3 months after surgery were compared between the two groups. Results After treatment, the levels of LVESD, LVEDD,PAF, and GDF-15 in the experimental group were lower than those in the reference group, and the level of LVEF in the experimental group was higher than that in the reference group, and the differences were statistically significant (P<0.05). The incidence of MACE in the experimental group at 3 months after surgery was lower than that in the reference group, the difference was statistically significant (P<0.05). Conclusion Tirofiban combined with Atorvastatin and dual antiplatelet drugs is effective in the treatment of patients with coronary atherosclerotic heart disease after PCI, which can effectively improve cardiac function and reduce the risk of MACE.